TRAIL combinations: The new 'trail' for cancer therapy (Review).
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy is anticipated to be one of the most effective cancer treatments. However, resistance to TRAIL therapy remains a challenge facing the development of anticancer strategies. To circumvent this problem, TRAIL combinations have been experimented with for over ten years to induce synergism or sensitize resistant cancer cells. By analyzing the signaling pathways triggered by these combinations, this review has defined a set of core targets for novel combinatorial treatments. The review suggests specific pathways to be targeted together with TRAIL for more efficient treatment, including cellular FLICE inhibitory protein and its downstream survival factors, the Bcl-2 family and other prominent targets. The suggested pathways provide new avenues for more effective TRAIL-based cancer therapy.
Center for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12588, Egypt.
Alaa
A
Refaat
Center for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12588, Egypt.
Ahmed
A
Abd-Rabou
Center for Aging and Associated Diseases, Zewail City of Science and Technology, Giza 12588, Egypt.
Asmaa
A
Reda
apoptosis; cancer therapy; death receptor 5; tumor necrosis factor related apoptosis-inducing ligand